Insights on the Biologics Contract Manufacturing Global Market to 2027 - Emergence of Single-use Bioprocessing Equipment & Solutions Presents Opportunities -

DUBLIN--()--The "Biologics Contract Manufacturing Market Research Report by Product (Biosimilar, Insulin, and Interferons), Platform, Therapeutic Area, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to's offering.

The Global Biologics Contract Manufacturing Market size was estimated at USD 16.92 billion in 2021 and expected to reach USD 19.64 billion in 2022, and is projected to grow at a CAGR 16.32% to reach USD 41.92 billion by 2027.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Biologics Contract Manufacturing Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Biologics Contract Manufacturing Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Biologics Contract Manufacturing Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Biologics Contract Manufacturing Market?

4. What is the competitive strategic window for opportunities in the Global Biologics Contract Manufacturing Market?

5. What are the technology trends and regulatory frameworks in the Global Biologics Contract Manufacturing Market?

6. What is the market share of the leading vendors in the Global Biologics Contract Manufacturing Market?

7. What modes and strategic moves are considered suitable for entering the Global Biologics Contract Manufacturing Market?

Market Dynamics


  • Increasing demand for biosimilars and vaccine production
  • Ongoing investment activities by CMOs for capacity expansion
  • Key advantages such as cost and time saving offered by contract services


  • Changing trade policies between countries


  • Emergence of single-use bioprocessing equipment & solutions
  • Rising demand for cell and gene therapies for targeted treatment


  • Concerns over the breach of intellectual property and patents

Companies Mentioned

  • AbbVie, Inc.
  • Abzena Plc.
  • AGC Biologics
  • Ajinomoto Co., Inc.
  • Avid Bioservices, Inc.
  • Binex Co., Ltd.
  • Boehringer Ingelheim GmbH
  • Cambrex Corporation
  • Catalent, Inc.
  • Emergent BioSolutions Inc.
  • Fujifilm Holding Corporation
  • JSR Life Sciences, LLC
  • Lonza Group AG
  • ProBioGen AG
  • Recipharm AB
  • Rentschler Biotechnologie GmbH
  • Samsung Biologics Co., Ltd.
  • Siegfried Holding AG
  • Thermo Fisher Scientific, Inc.
  • Toyobo Co. Ltd.
  • WuXi Biologics Inc.

For more information about this report visit

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900